Triveni Bio launch­es with $92M Se­ries A to fund eczema an­ti­body treat­ment

Triveni Bio has raised $92 mil­lion in a Se­ries A fi­nanc­ing round as it aims to move its atopic der­mati­tis an­ti­body in­to the clin­ic.

At­las Ven­ture and Cor­morant As­set Man­age­ment led the round, with Mass­a­chu­setts-based Triveni aim­ing to move TRIV-509 in­to the clin­ic in 2025 and a Phase IIa tri­al in atopic der­mati­tis in 2027. It al­so ex­pects to nom­i­nate two oth­er an­ti­body can­di­dates in 2024 that fo­cus on oth­er im­muno­log­i­cal and in­flam­ma­to­ry dis­or­ders. The com­pa­ny’s cash run­way is now set to last in­to 2027.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER